Jens Grueger, PhD, joins Curta as Senior Advisor for Global Evidence, Value, Pricing, and Access Strategies
SEATTLE, May 1, 2025 /PRNewswire/ -- Curta, a market leader in strategy and evidence generation to meet health policy, market access and commercialization needs in life sciences, accelerates its global growth with the addition of Jens Grueger, a renowned expert in health economics and market access as an expert advisor.
Dr. Grueger, a distinguished figure in the pharmaceutical industry, renowned for his extensive expertise in global market access, pricing, and health economics, joins Curta May 1, 2025 as Senior Advisor for Global Evidence, Value, Pricing, and Access Strategies. Dr. Grueger will work closely with the Curta Global Market Access team, led by Dr. Sean Sullivan, to help life sciences companies ensure that their products reach the patients who will benefit from them. "Jens Grueger brings unmatched expertise in global market access and value-based pricing—critical areas as the healthcare landscape grows increasingly complex. His leadership will enhance Curta's ability to deliver strategic guidance that accelerates commercialization and optimizes market success for our clients. Jens's track record with top-tier pharmaceutical companies and global stakeholders adds a new dimension to Curta's value proposition as we expand our footprint and deepen our impact across international markets," said Sean Sullivan, President at Curta.
Jens Grueger, PhD, has over 40 years of experience in the pharmaceutical industry, with a focus on global market access, pricing, and health economics. He has held senior roles at major pharmaceutical companies, including Senior Vice President and Head of Global Access at Roche (2011–2019), Vice President and Head of Global Market Access Primary Care at Pfizer (2009–2011), and Head of Global Pricing & Health Economics at Novartis (1999–2009). In these positions, he led the development and implementation of value-based pricing approaches, including risk-sharing and performance-based models, designed to support patient access to innovative therapies. In 2019, Dr. Grueger joined the Boston Consulting Group as Director and Partner, serving as a senior expert in pricing and market access within the life sciences sector. He is currently an Affiliate Professor of Health Economics at the University of Washington's CHOICE Institute and served as President of ISPOR during the 2020–2021 term.
"We are honored to welcome Jens Grueger as an expert advisor," said Dr. Lisa Bloudek, CEO of Curta. "His proven leadership in global access and pricing will expand our ability to deliver high-impact strategies that drive market success and long-term value for our clients." Dr. Grueger's experience and guidance will further strengthen Curta's commitment to delivering innovative, evidence-based solutions that address the complex challenges of global healthcare markets.
About Curta
People you know. Work you trust. Curta is a research partner specializing in evidence generation to support Health Policy, Market Access, Medical Affairs, and Commercialization teams in healthcare. Curta partners with biopharma companies to generate evidence through economic modeling, real-world data, evidence synthesis, and digital health strategies—helping demonstrate product value and inform access decisions worldwide. As a fully partner-owned organization, Curta combines scientific integrity with the ability to develop innovative, tailored approaches that address client needs and evolving payer requirements.
Learn more at Curta.com
SOURCE Curta Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article